These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Identification of interaction between PAI-2 and IRF-3. Zhang YQ, Li P, Hou M, Wang X, Fan J, Tan L, Zhu YS. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Jul; 35(7):661-5. PubMed ID: 12883638 [Abstract] [Full Text] [Related]
6. The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2. Medcalf RL, Stasinopoulos SJ. FEBS J; 2005 Oct; 272(19):4858-67. PubMed ID: 16176260 [Abstract] [Full Text] [Related]
7. Differential mechanisms of plasminogen activator inhibitor-1 gene activation by transforming growth factor-beta and tumor necrosis factor-alpha in endothelial cells. Chen YQ, Sloan-Lancaster J, Berg DT, Richardson MA, Grinnell B, Tseng-Crank J. Thromb Haemost; 2001 Dec; 86(6):1563-72. PubMed ID: 11776328 [Abstract] [Full Text] [Related]
19. Aberrant expression of serpin squamous cell carcinoma antigen 2 in human tumor tissues and cell lines: evidence of protection from tumor necrosis factor-mediated apoptosis. Takeda A, Kajiya A, Iwasawa A, Nakamura Y, Hibino T. Biol Chem; 2002 Apr; 383(7-8):1231-6. PubMed ID: 12437110 [Abstract] [Full Text] [Related]
20. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. McGowen R, Biliran H, Sager R, Sheng S. Cancer Res; 2000 Sep 01; 60(17):4771-8. PubMed ID: 10987285 [Abstract] [Full Text] [Related] Page: [Next] [New Search]